● Recruiting

Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM

Condition: Hypertrophic Cardiomyopathy · Sponsor: Tenaya Therapeutics

PhasePhase 1/Phase 2

Planned participants30

Who can joinAll sexes, 18 Years to 75 Years

Healthy volunteersNo

About this study

This is a first-in-human, non-randomized, open-label study designed to evaluate the safety, tolerability, and pharmacodynamics (PD) of TN-201 in adult patients with symptomatic hypertrophic cardiomyopathy (HCM) caused by mutations in the MYBPC3 gene.

This description comes directly from the study's public registry record.

Talk to the study team

Matt Pollman, M.D. · 650-209-8092 · mpollman@tenayathera.com

LaTanya Tomlinson, RN, MHSA · 650-825-6990 · clinical.trials@tenayathera.com

Always discuss trial participation with your own doctor first.

Locations (10)

UC San Diego Altman Clinical and Translational Research Institute - Center for Clinical Research	La Jolla, California, United States	Recruiting
University of California San Francisco	San Francisco, California, United States	Recruiting
Emory University	Atlanta, Georgia, United States	Withdrawn
Brigham and Women's Hospital	Boston, Massachusetts, United States	Withdrawn
Mayo Clinic	Rochester, Minnesota, United States	Recruiting
The Christ Hospital Physicians - The Ohio Heart and Vascular Center	Cincinnati, Ohio, United States	Withdrawn
Cleveland Clinic	Cleveland, Ohio, United States	Recruiting
Oregon Health & Science University	Portland, Oregon, United States	Withdrawn
Hospital of the University of Pennsylvania	Philadelphia, Pennsylvania, United States	Withdrawn
Houston Methodist Hospital	Houston, Texas, United States	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05836259